Catalog No.: PC-49158Not For Human Use, Lab Use Only.
JND003 is a potent, selective and orally bioavailable ERRα agonist with EC50 of 86.0 nM for enhancing the interaction between ERRα and PGC1α peptide in AlphaScreen assays, exhibits an EC50 value of 2.7 uM in AAB-Luc cells stably expressing ERRα luciferase reporter.
JND003 is a potent, selective and orally bioavailable ERRα agonist with EC50 of 86.0 nM for enhancing the interaction between ERRα and PGC1α peptide in AlphaScreen assays, exhibits an EC50 value of 2.7 uM in AAB-Luc cells stably expressing ERRα luciferase reporter.
JND003 (5.0 μM) potently and selectively agonizes the transcriptional function of ERRα in AAB-Luc cells, displays no obvious effect on ERRβ and ERRγ, as well as other nuclear hormone receptors, such as ERα, ERβ, ERγ and PPARγ.
JND003 (10.0 μM) reduces lipid accumulation and enhances fatty acid oxidization in HepG2-IR cells.
JND003(30mg/kg, oral) exhibits high grade of distribution in liver and abdominal adipose tissues， improves insulin sensitivity, alleviates liver steatosis and serum lipid disorders in HFD-fed C57 mice.
Physicochemical Properties
M.Wt
266.300
Formula
C16H14N2O2
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
7-methoxy-3-methyl-2-phenyl-4(3H)-Quinazolinone
References
1. Liufeng Mao, et al. ACS Bio Med Chem Au. 2022 Jun 15;2(3):282-296.
